Median (range) age at T0 (years) | 35.4 (16.4–62.4) | 34.6 (15.7–77.8) | |
Sex (% women) | 85.3 | 90.2 | |
Ethnicity (%) | | | |
Hispanic Texas (n = 55) | 20.8 | 27.9 | |
Hispanic Puerto Rico (n = 25) | 13.1 | 1.6 | 0.0014 |
African American (n = 93) | 33.0 | 50.8 | |
Caucasian (n = 71) | 32.2 | 19.7 | |
Health insurance (%) | 82.2 | 61.8 | 0.0016 |
Median (range) education (years) | 12.0 (5.0–20.0) | 12.0 (3.0–17.0) | 0.0002 |
Below poverty line (%) | 26.1 | 56.0 | <0.0001 |
Smoking (%) | 14.8 | 17.9 | |
Median (range) disease duration at T0 (months) | 11.4 (0.3–75.4) | 7.0 (0.2–59.1) | 0.0525 |
Median (range) disease duration at TL (months) | 53.1 (0.7–146.2) | 48.9 (0.4–141.4) | |
Median (range) follow-up time (T0–TL) (months) | 41.8 (0.4–145.9) | 41.9 (0.2–144.2) | |
Median (range) number of ACR criteria at diagnosis | 5.0 (4.0–10.0) | 6.0 (4.0–9.0) | 0.0323 |
Clinical manifestations (%) | | | |
Integument | 88.0 | 78.7 | 0.0736 |
Arthritis | 78.5 | 68.3 | |
Pleuritis or pericarditis | 38.9 | 71.7 | <0.0001 |
Pulmonary disease | 8.3 | 18.6 | 0.0265 |
Renal disease | 33.3 | 63.3 | <0.0001 |
Immune-mediated cytopenias | 77.2 | 89.1 | 0.0551 |
CNS involvement | 29.1 | 53.3 | 0.0007 |
Myositis | 7.3 | 23.3 | 0.0007 |
Median (range) SLAM-R at T0 | 8.0 (0–30.0) | 14.0 (2.0–31.0) | <0.0001 |
Median (range) SDI at T0 | 0 (0–5.0) | 1.0 (0–5.0) | <0.0001 |
Anti-ds DNA antibodies (%) | 27.0 | 42.4 | 0.0322 |
Antiphospholipid antibodies (%) | 25.1 | 26.2 | |
HLA-DRB1*08 (%) | 11.4 | 10.2 | |
Hospitalisations due to SLE (%) | 24.8 | 56.6 | <0.0001 |
ER visits due to SLE (%) | 22.5 | 52.8 | <0.0001 |
Glucocorticoid use (%) | 89.6 | 88.5 | |
Azathioprine use (%) | 9.8 | 14.8 | |
Cyclophosphamide use (%) | 14.2 | 26.2 | 0.0316 |
Low dose aspirin and/or anticoagulant use† (%) | 27.3 | 21.3 | |
Median (range) IBQ total score at T0 | 20.0 (3.0–35.0) | 19.5 (5.0–31.0) | |